Aripiprazole

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 12, 2005, Pages 2091-2101

  Fleischhacker, W Wolfgang ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ADRENERGIC RECEPTOR; ARIPIPRAZOLE; CARBAMAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; CYTOCHROME P450; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; GLUCOSE; HALOPERIDOL; HISTAMINE RECEPTOR; LIPID; LIVER ENZYME; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRANQUILIZER; TRIACYLGLYCEROL; UNINDEXED DRUG; ZIPRASIDONE;

AKATHISIA; ARTICLE; BIPOLAR DISORDER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DYSLIPIDEMIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; METABOLIC DISORDER; METABOLIC SYNDROME X; MUSCLE HYPERTONIA; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSONISM; RECEPTOR AFFINITY; RELAPSE; RESTLESSNESS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TABLET FORMULATION; TARDIVE DYSKINESIA; TREATMENT INDICATION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 27744477271     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.12.2091     Document Type: Article

References (64)

1. FLEISCHHACKER WW: New developments in the pharmacotherapy of schizophrenia. J. Neural. Transm. (2003) 64(Suppl.):107-117.
2. SWAINSTON-HARRISON TS, PERRY CM: Aripiprazole - a review of its use in schizophrenia and schizoaffective disorder. Drugs (2004) 64:1715-1736.
3. MCGAVIN JK, GOA KL: Aripiprazole. CNS Drugs (2002) 16:779-786.
4. LAWLER C, PRIOLEAU C, LEWIS MM et al.: Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology (1999) 20:612-627.
5. KIKUCHI T, TOTTORI K, UWAHODO Y et al.: 7-{4-[-(2,3-dichlorophenyl)-l-piperazinyl] butyloxy}-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonist activity and postsynaptic D2 receptor antagonist activity. J. Pharmacol. Exp. Ther. (1995) 274:329-336.
6. BURRIS KD, MOLSKI TF, XU C et al.: Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. (2002) 302:381-389.
7. JORDAN S, KOPRIVICA V, CHEN R et al.: The antipsychotic aripiprazole is a potent, partial agonist at the human 5HT1A receptor. Eur. J. Pharmacol. (2002) 441:137-140.
8. JORDAN S, KOPRIVICA V, DUNN R et al.: In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur. J. Pharmacol. (2004) 483:45-53.
9. KIKUCHI T, UWAHODO Y, TOTTORI K et al.: Behavioral pharmacological studies of OPC-14597, a novel antipsychotic drug: comparison with OPC-4392, clozapine and haloperidol. Jpn. J. Pharmacol. (1996) 71(Suppl. I):185P.
10. UWAHODO Y, KIKUCHI T, TOTTORI K et al.: Pharmacological profile of OPC-14597, a novel antipsychotic drugs (2): weak extrapyramidal side effects. Jpn. J. Pharmacol. (1995) 67(Suppl. I):144P.
11. MALLIKAARJUN S, SALAZAR DE, BRAMER SL: Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J. Clin. Pharmacol. (2004) 44:179-187.
12. BOULTON D, MALLIKAARJUN S, VANDERSLICE T et al.: Effects of aripiprazole on the steady-state pharmacokinetics of valproic acid. Eur. Neuropsychopharmacol. (2004) 14(Suppl. 3):S291.
13. BRAMER S, SHOAF S, SALAZAR DE et al.: Effects of renal and hepatic impairment on the pharmacokinetics of aripiprazole. Eur. Neuropsychopharmacol. (2003) 13(Suppl. 4):S333.
14. MALLIKAARJUN S, RIESGO Y, SALAZAR DE et al: Effect of time of dosing and food on aripiprazole pharmacokinetics. Eur. Neuropsychopharmacol. (2003) 13(Suppl. 4):S332.
15. CITROME L, JOSIASSEN R, BARK N et al.: Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J. Clin. Pharmacol. (2005) 45:89-93.
16. KANE JM, CARSON WH, SAHA AR et al.: Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry (2002) 6.3:763-771.
17. MARDER SR, MCQUADE RD, STOCK E et al.: Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia Res. (2003) 61:123-136.
18. POTKIN SG, SAHA AR, KUJAWA MJ et al.: Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone versus placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry (2003) 60:681-690.
19. CARSON WH, ARCHIBALD DG, MANOS G et al.: Short-term efficacy of aripiprazole on depression/anxiety in schizophrenia. Poster presented at the American Psychiatric Association Annual Meeting (2003).
20. DILLENSCHNEIDER A, MARCUS R, KOSTIC D et al.: Short and long-term effects of aripiprazole treatment on the excitement/hostility symptoms of schizophrenia. Int. J. Neuropsychopharmacol. (2004) 7(Suppl. 1):S243
21. LOZE JV, KOSTIC D, MCQUADE R et al.: The effects of aripiprazole on the cognitive symptoms of schizophrenia. Eur. Neuropsychopharmacol. (2004) 14(Suppl. 3):S287.
22. KUJAWA M, STRINGFELLOW J, HARDY S et al.: Efficacy, safety, and tolerability of aripiprazole in patients with schizoaffective disorder. Schizophr. Res. (2004) 67(Suppl. 1):305.
23. JODY D, TANDON R, STOCK E et al.: A naturalistic study of aripiprazole treatment in a general psychiatric setting. Int. J. Neuropsychopharmacol. (2004) 7(Suppl. 1):S242.
24. CARSON W, MARCUS R, JODY D et al.: The effectiveness of switch to aripiprazole stratified by prior antipsychotic. Poster presented at the American Psychiatric Association Annual Meeting. New York, NY (1-6 May, 2004).
25. MODELL S, JODY D, KUJAWA M et al.: Efficacy of aripiprazole and perphenazine in severe schizophrenia resistant to treatment with atypical antipsychotics. Eur. Neuropsychopharmacol. (2004) 14(Suppl. 3):S265.
26. KANE J, CARSON W, KUJAWA M et al.: Aripiprazole vs perphenazine in treatment resistant schizophrenia. Poster presented at the American Psychiatric Association Annual Meeting (2003).
27. CASEY DA, CARSON WH, SAHA AR et al.: Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (2003) 166:391-399.
28. PIGOTT TA, CARSON WH, ANUTOSH RS et al.: Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J. Clin. Psychiatry (2003) 64:1048-1056.
29. KASPER S, LERMAN MN, MCQUADE RD et al.: Efficacy and safety of aripiprazole versus haloperidol for long-term maintenance treatment following acute relpase of schizophrenia. Int. J. Neuropsychopharmacol. (2003) 6:325-337.
30. MCQUADE RD, STOCK E, MARCUS R et al.: A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J. Clin. Psychiatry (2004) 65(Suppl. 18):47-56.
31. MCQUADE R, KOSTIC D, MARCUS R et al.: Aripiprazole versus olanzapine in schizophrenia: a 52-week, open-label extension study. Poster presented at the American College of Neuropsychopharmacology 43rd Annual Meeting. San Juan, Puerto Rico (12-16 December, 2004).
32. CORNBLATT B, CARSON WH, ALI M et al.: Neurcognitive effects of aripiprazole versus olanzapine in stable psychosis. Int. J. Neuropsychopharmacol. (2002) 5(Suppl. 1):S185.
33. LINDSEY RL, KAPLAN D, KOLIATSOS V et al.: Ariprazole and extrapyramidal symptoms. J. Am. Acad. Child Adolesc. Psychiatry (2003) 42:1268-1269.
34. SCHONBERGER RB, DOUGLAS L, BAUM CR et al.: Severe extrapyramidal symptoms in a 3-year-old boy after accidental ingestion of the new antipsychotic drug aripiprazole. Pediatrics (2004) 114:1743.
35. DUGGAL HS: Aripiprazole-induced improvement in tardive dyskinesia. Can. J. Psychiatry (2003) 48:771-772.
36. DAVENPORT JD, McCARTHY MW, BUCK ML: Excessive somnolence from aripiprazole in a child. Pharmacotherapy (2004) 24:522-525.
37. SPALDING S, ALESSI NE, RADWAN K: Aripiprazole and atypical neuroleptic malignant syndrome. J. Am. Acad. Child Adolesc. Psychiatry (2004) 43:1457-1458.
38. CHAKRABORTY N, JOHNSTON T: Aripiprazole and neuroleptic malignant syndrome. Int. Clin. Psychopharmacol. (2004) 19:351-353.
39. CASEY DA, L'ITALIEN G, CISLO P: Comparative one-year incidence/worsening of metabolic syndrome among patients treated with olanzapine versus aripiprazole. Poster presented at the American Psychiatric Association Annual Meeting. New York, NY (1-6 May, 2004).
40. AMERICAN DIABETES ASSOCIATION, AMERICAN PSYCHIATRIC ASSOCIATION, AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS et al.: Consensus development conference on antipsychotic drugs, obesity and diabetes. Diabetes Care (2004) 27:596-601.
41. BERK M, DODD S: Efficacy of atpical antipsychotics in bipolar disorder. Drugs (2005) 65: 257-269.
42. MCQUADE R, SANCHEZ R, CARSON W et al.: Efficacy of aripiprazole versus placebo in acute mania: pooled analysis. Poster presented at the American Psychiatric Association Annual Meeting. New York, NY (1-6 May, 2004).
43. KECK PE, MARCUS R, TOURKODIMITRIS S et al.: A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am. J. Psychiatry (2003) 160:1651-1658.
44. VIETA E, BOURIN M, SANCHEZ R et al.: Effectiveness of aripiprazole versus haloperidol in acute bipolar mania. Er. J. Psychiatry (2005) 187:235-242.
45. MCQUADE R, SANCHEZ R, MARCUS R et al.: Aripiprazole for relapse prevention in bipolar disorder in a 26-week placebo-controlled study. Int. J. Neuropsychopharmacol. (2004) 7(Suppl. 1):S160.
46. SACHS G, SANCHEZ R et al.: Aripiprazole vs placebo with an acute manic or mixed episode. Poster presented at the American Psychiatric Association Annual Meeting (2004).
47. ABOU-GHARBIA N, MARCUS R, CARSON W et al.: Safety and tolerability of aripiprazole in acute mania: pooled data. Int. J. Neuropsychopharmacol (2004) 7(Suppl. 1):S328.
48. KOSTIC D, BREDER C, SWANINK R et al.: A dose-ranging study of aripiprazole treatment in patients with psychosis associated with Alzheimer's dementia. Eur. Neuropsychopharmacol. (2004) 14(Suppl. 3):S260.
49. STREIM J, BREDER C, SWANINK R et al.: Flexible dose aripiprazole in psychosis of Alzheimer's dementia. Poster presented at the American Psychiatric Association Annual Meeting. New York, NY (1-6 May, 2004).
50. DE DEYN P, JESTE DV, SWANINK R et al.: Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. J. Clin. Psychopharmacol. (2005) 25:463-467.
51. GUPTA S, CHOHAN M, MADHUSOODANAN S: Treatment of acute mania with aripiprazole in an older adult with noted improvement in coexisting Parkinson's disease. Prim. Care Companion J. Clin. Psychiatry (2004) 6:50-51.
52. SCHONFELDT-LECUONA C, CONNEMANN BJ: Aripiprazole and Parkinson's disease psychosis. Am. J. Psychiatry (2004) 161:373-374.
53. FERNANDEZ HH, TRIESCHMANN ME, FRIEDMAN JH: Aripiprazole for drug-induced psychosis in Parkinson's disease: preliminary experience. Clin. Neuropharmacol. (2004) 27:4-5.
54. FINDLING RL, BLUMER JL, KAUFFMAN R et al.: Pharmacokinetic effects of aripiprazole in children and adolescents with conduct disorder. Int. J. Neuropsychopharmacol. (2004) 7(Suppl. 1):S441.
55. STALLER JA: Aripiprazole in an adult with Asperger disorder. Ann. Pharmacother. (2003) 37:1628-1631.
56. MYERS WC, RUIZ R: Aripiprazole and psychotherapy for delusional disorder, erotomanic type. J. Am. Acad. Child Adolesc. Psychiatry (2004) 43:1069-1070.
57. GOFORTH HW, RAO M, SUCHOLEIKI R: Chronic interictal psychosis responsive to aripiprazole. J. Clin. Psychopharmacol. (2004) 24:573-574.
58. WORTHINGTON JJ III, KINRYS G, WYGANT LE et al.: Aripiprazole as an augmentor of selective serotonin-reuptake inhibitors in depression and anxiety disorder patients. Int. Clin. Pychopharmacol. (2005) 20:9-11.
59. ADSON DE, KUSHNER MG, FAHNHORST TA: Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J. Affect. Disord. (2005) 86(1):99-104.
60. DUGGAL HS: Aripiprazole-olanzapine combination for treatment of schizophrenia. Can. J. Psychiatry (2004) 49:151.
61. VACHHARAJANI N, VANDERSLICE T, KOLLIA G et al.: Bioavailability of an oral solution of the antipsychotic aripiprazole. Poster presented at the American Psychiatric Association Annual Meeting (2004).
62. SCOTT K, BOULTON D, DRESSLER D et al.: Bioequivalence of an orally disintegrating tablet compared to the oral tablet formation of the antipsychotic aripiprazole. Eur. Neuropsychopharmacol. (2004) 14(Suppl. 3):S287.
63. MODELL S, DANIEL D, STOCK E et al.: Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. Int. J. Neuropsychopharmacol. (2004) 7(Suppl. 1):S417.
64. YOCCA F, MARCUS R, OREN D et al.: Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. Poster presented at the American Psychiatric Association Annual Meeting (2005).